NRG
FLGT icon

Nemes Rush Group’s Fulgent Genetics FLGT Stock Holding History

Nemes Rush Group’s Portfolio FLGT Stock Details FLGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-13
Closed -$282 – 754
2024
Q3 		$282 Buy
+13
New +$291 ﹤0.01% 584
2024
Q2 		– Sell
-13
Closed -$283 – 633
2024
Q1 		$283 Buy
+13
New +$323 ﹤0.01% 645

Other funds holding FLGT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Nemes Rush Group's FLGT Position: Q4 2024 in Review

Nemes Rush Group sold out of Fulgent Genetics (FLGT) in Q4 2024, closing a stake of 13 shares — an estimated $282 sold.

Nemes Rush Group first reported a position in FLGT in Q1 2024 and held it in 2 quarters. The position peaked at $283 in Q1 2024. 189 funds tracked by Wall St. Rank hold FLGT as of Q4 2024.

  • Nemes Rush Group reported no remaining Fulgent Genetics position as of Q4 2024 after selling out during the quarter.
  • Nemes Rush Group sold 13 Fulgent Genetics shares in Q4 2024, an estimated $282.
  • Nemes Rush Group first reported a position in Fulgent Genetics in Q1 2024 and held it in 2 quarters.
  • Nemes Rush Group's Fulgent Genetics position peaked at $283 in Q1 2024.
  • 189 funds tracked by Wall St. Rank held Fulgent Genetics as of Q4 2024.

Based on Nemes Rush Group's 13F filing for Q4 2024, filed 12 Feb 2025.